top of page
Cover_edited.jpg

Developing a novel treatment 
for ocular Epidermolysis Bullosa

Navigating Epidermolysis Bullosa

Understanding the Challenges and Solution

Epidermolysis Bullosa (EB) is an ultra-rare genetic disorder characterized by fragility of the eyes and skin, making them prone to blistering and tearing from minor friction or trauma. This condition primarily affects children, presenting a lifelong challenge that demands specialized care and attention.​​

​

The ocular manifestations of this condition are profound and painful, and if left unaddressed, they can lead to blindness. Recognizing the pivotal role of ocular health in patient quality of life, we're driven to forge solutions that address this unmet need.

ELK-003
Eye drops for Epidermolysis Bullosa

RDD que usamos.png

ELK-003 is an experimental biological drug 

currently in a clinical trial for the treatment of ocular manifestations of EB.

Social Media Posts (2).png

Join our Patient Advisory Group for ELK-003!

Thanks for submitting!

CONTACT US

Pennsylvania Biotechnology Center

3805 Old Easton Rd

Doylestown, PA 18902

  • X
  • LinkedIn
  • Instagram
  • Facebook

© 2025 by Eliksa Therapeutics, Inc.

SUBSCRIBE

Sign up to receive Eliksa's news and updates.

Thanks for submitting!

bottom of page